By admin 
Expedition Therapeutics, a rapidly emerging biotechnology company focused on bringing innovative therapies to market, announced Wednesday it has successfully closed a $115 million Series B financing round. This significant capital infusion is earmarked to propel its lead experimental medicine, EXPD-101, through crucial mid-stage clinical testing for chronic obstructive pulmonary disease (COPD). The drug, originally licensed from China’s Fosun Pharma, exemplifies a growing strategic trend in the biotech sector: leveraging the burgeoning pharmaceutical innovation emanating from China to address global unmet medical needs.
Expedition Therapeutics: A New Model for Global Drug Development
Expedition Therapeutics formally launched its operations in 2024 with a distinctive business model centered on in-licensing promising drug candidates from Chinese pharmaceutical companies and subsequently guiding them through rigorous clinical development and commercialization in global markets. This strategy positions Expedition at the forefront of a pivotal shift in the biopharmaceutical landscape, where investors are increasingly forming new companies specifically designed to harness the vast and rapidly expanding reservoir of drug discovery and development capabilities within China. The successful Series B round brings Expedition’s total capital raised to $280 million, following a robust $165 million Series A funding round secured last year, underscoring strong investor confidence in its approach and pipeline.
The company’s foundational partnership was established with Fosun Pharma, a major Chinese pharmaceutical conglomerate. This collaboration granted Expedition Therapeutics exclusive rights across most of the globe for EXPD-101, a compound previously designated as XH-S004 by Fosun, which had been developing it for the treatment of COPD. This strategic alliance highlights the reciprocal benefits of such cross-border licensing deals: Chinese innovators gain access to global development expertise and market reach, while Western biotechs acquire de-risked assets with established preclinical or early clinical data, potentially at more favorable terms than domestically developed compounds.
EXPD-101: Targeting Neutrophilic Inflammation in COPD
EXPD-101 operates by targeting an enzyme known as Dipeptidyl Peptidase 1 (DPP1). DPP1 plays a critical role in activating certain proteases within neutrophils, a type of white blood cell essential for the body’s immune response against infections. While neutrophils are vital for host defense, their overstimulation or dysregulation can lead to chronic inflammation and tissue damage, particularly in the lungs. By stifling the activity of DPP1, EXPD-101 aims to modulate this neutrophilic inflammation, thereby holding significant promise for the treatment of various respiratory conditions, including COPD.
Chronic Obstructive Pulmonary Disease is a progressive lung disease characterized by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases. It is a leading cause of morbidity and mortality worldwide, imposing a substantial economic and social burden. According to the World Health Organization (WHO), COPD is the third leading cause of death globally, responsible for 3.23 million deaths in 2019. The disease impacts hundreds of millions of people globally, with prevalence rates rising due to factors such as smoking, air pollution, and occupational exposures. Current treatments primarily focus on symptom management, reducing exacerbations, and improving quality of life, but there remains a significant unmet need for therapies that can modify disease progression or address underlying inflammatory drivers more effectively.
The Emerging Promise of DPP1 Inhibition
The therapeutic potential of DPP1 inhibition has garnered considerable attention from multiple pharmaceutical developers in recent years. A notable precedent in this class is Insmed’s brensocatib, marketed as Brinsupri. Insmed licensed this DPP1-targeting drug from AstraZeneca approximately a decade ago and has successfully brought it to market as a treatment for bronchiectasis, a chronic lung condition characterized by permanent enlargement of parts of the airways. Brinsupri has been heralded as a significant advancement for bronchiectasis patients and is widely projected to achieve blockbuster status, exceeding $1 billion in annual sales. Its success has served to validate DPP1 as a viable and attractive therapeutic target for inflammatory lung diseases.
Beyond Insmed, other major players are also exploring DPP1 inhibitors. Boehringer Ingelheim has compounds in its pipeline, and a partnership between Chiesi and Haisco Pharmaceutical is also advancing its own DPP1 inhibitor through clinical testing for bronchiectasis. The competitive landscape within this drug class underscores the perceived efficacy and safety profile of targeting DPP1 for chronic respiratory inflammation, creating a fertile ground for new entrants like Expedition Therapeutics.
Leadership and Strategic Vision
Expedition Therapeutics is spearheaded by CEO Yi Larson, a seasoned executive with a distinguished background spanning investment banking and biotech leadership. Larson’s career includes significant roles and board seats at high-profile biotech firms such as Turning Point Therapeutics and RayzeBio, both of which were ultimately acquired by Bristol Myers Squibb in multi-billion-dollar deals. Her experience, particularly in guiding companies through critical development phases and strategic transactions, is invaluable to Expedition’s mission.
Larson articulated her belief that EXPD-101, as a DPP1 inhibitor, holds broader potential beyond conditions like bronchiectasis, specifically for addressing COPD, which she described as one of the world’s most common inflammatory lung diseases. She highlighted the current therapeutic landscape for COPD, which has seen the approval of several new therapies since 2024, including Regeneron Pharmaceuticals and Sanofi’s Dupixent, GSK’s Nucala, and Verona Pharma’s Ohtuvayre. While these represent important advancements, many are injectable biologics or require specific delivery mechanisms.
Larson emphasized the distinctive advantages of EXPD-101: as a once-daily oral pill, it offers a more convenient and potentially less invasive alternative to existing injectable therapies or inhalers. Crucially, she noted that EXPD-101 could benefit a broader spectrum of COPD patients, referred to as the "whole population," because it directly targets a specific kind of "neutrophilic" inflammation that certain other biologics do not adequately address. "You take this pill once a day, and it can target that underlying inflammation that all the COPD patients have," Larson stated, expressing confidence that EXPD-101 "felt like it could become a backbone of care for patients."
Clinical Development and Future Milestones
Expedition Therapeutics has already initiated the recruitment of volunteers for what it claims is the first global Phase 2 trial of a DPP1 inhibitor specifically for COPD. This is a critical step in validating EXPD-101’s efficacy and safety in a larger patient population and demonstrating its potential as a foundational treatment. According to information available on a federal clinical trials database (NCT07684820), initial data from this pivotal study are anticipated in 2028. The successful progression through Phase 2 will be a key determinant of the drug’s future development and potential regulatory pathways.
Investor Confidence and Strategic Partnerships
The Series B financing round was led by General Atlantic, a leading global growth equity firm, signaling robust investor confidence in Expedition’s strategy and scientific promise. General Atlantic was joined by a syndicate of prominent new and existing investors, including Vivo Capital, RA Capital Management, Forbion, Sofinnova Investments, Novo Holdings, and Venrock. The participation of such a diverse and experienced group of life sciences investors underscores the perceived value and potential impact of Expedition’s pipeline.
As part of the financing, Brett Zbar, a managing director at General Atlantic, will join Expedition Therapeutics’ board of directors. Zbar’s appointment brings additional strategic guidance and financial expertise to the company’s leadership. General Atlantic has a notable history of backing high-profile private and public biotech companies over the past five years. Its portfolio includes Akero Therapeutics, which was acquired by Novo Nordisk in 2025; Seaport Therapeutics, which successfully went public earlier this year; and Verdiva Bio, another company built around in-licensed assets from China, demonstrating a pattern of strategic investment in companies leveraging global innovation.
Zbar openly discussed General Atlantic’s strategic rationale, stating that the firm has "benefited from the good fortune of having a team and a real presence in China," which has enabled them to identify and invest in "first or best-in-class assets" originating from the region. This statement highlights a broader investment trend where sophisticated capital is actively seeking out and nurturing biotech innovation regardless of its geographic origin, particularly recognizing the rapid advancements made in China’s life sciences sector.
The Rise of China as a Global Biotech Hub
The emergence of companies like Expedition Therapeutics is not an isolated phenomenon but rather a reflection of China’s transformation into a significant global hub for pharmaceutical innovation. Over the past two decades, China has invested heavily in its biotechnology and pharmaceutical sectors, fostering a vibrant ecosystem of academic research, government support, and private enterprise. This has led to a dramatic increase in novel drug discovery, with Chinese companies now developing a substantial number of innovative drug candidates, many of which are first-in-class or best-in-class within their respective therapeutic areas.
Factors contributing to this rise include:
- Increased R&D Investment: Significant government and private sector funding poured into research and development.
- Talent Pool: A rapidly expanding pool of highly educated scientists, clinicians, and entrepreneurs.
- Favorable Regulatory Environment: Streamlined regulatory pathways for innovative drugs within China, encouraging domestic development.
- Large Patient Population: Access to a vast patient population for clinical trials, accelerating recruitment.
- Manufacturing Capabilities: Robust and cost-effective manufacturing infrastructure.
For Western biotech companies, in-licensing assets from China presents a compelling value proposition. It offers access to a diverse pipeline of de-risked compounds that have often undergone initial proof-of-concept studies, potentially at more attractive terms than those available from traditional Western sources. This model allows companies like Expedition to focus their resources on later-stage clinical development, regulatory navigation, and market access, thereby accelerating the path to patients. Conversely, Chinese pharmaceutical companies benefit from partnerships that provide global development expertise, regulatory knowledge for international markets, and access to Western capital, which can be crucial for maximizing the global potential of their innovations.
Broader Implications for the Pharmaceutical Industry
Expedition Therapeutics’ successful funding round and its strategic focus have broader implications for the global pharmaceutical industry. It underscores a fundamental shift towards a more interconnected and globally integrated drug development ecosystem. The traditional model of innovation primarily flowing from West to East is evolving into a more bidirectional exchange, with China emerging as a significant source of novel therapeutic concepts.
This trend is likely to intensify competition in key therapeutic areas, accelerate the pace of drug development, and potentially lead to more affordable and accessible medicines globally. For patients suffering from debilitating diseases like COPD, the emergence of innovative therapies like EXPD-101, regardless of their origin, represents a beacon of hope for improved treatment options and better quality of life. As Expedition Therapeutics advances EXPD-101 through its global Phase 2 trials, the industry will be closely watching, anticipating not only the potential impact of this specific drug but also the continued validation of a groundbreaking model for global biotech innovation.
